uniQure Faces Class Action Lawsuit for Securities Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy QURE?
Source: PRnewswire
- Class Action Reminder: DJS Law Group alerts investors of a class action lawsuit against uniQure N.V. (NASDAQ:QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act, covering the trading period from September 24, 2025, to October 31, 2025, with a deadline for participation by April 13, 2026.
- False Statements Allegation: The complaint alleges that uniQure made false and misleading statements regarding its pivotal study design, failing to achieve full FDA approval and underestimating potential delays in its BLA application, which materially misled investors during the class period.
- Investor Losses: Affected shareholders are encouraged to contact DJS Law Group to participate in the recovery process, noting that appointment as lead plaintiff is not a prerequisite for participation, thus providing broader access for investors to seek redress.
- Legal Expertise: DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through balanced counseling and aggressive advocacy, attracting some of the largest hedge funds and alternative asset managers as clients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 15.600
Low
33.00
Averages
49.88
High
70.00
Current: 15.600
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: DJS Law Group alerts investors of a class action lawsuit against uniQure N.V. (NASDAQ:QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act, covering the trading period from September 24, 2025, to October 31, 2025, with a deadline for participation by April 13, 2026.
- False Statements Allegation: The complaint alleges that uniQure made false and misleading statements regarding its pivotal study design, failing to achieve full FDA approval and underestimating potential delays in its BLA application, which materially misled investors during the class period.
- Investor Losses: Affected shareholders are encouraged to contact DJS Law Group to participate in the recovery process, noting that appointment as lead plaintiff is not a prerequisite for participation, thus providing broader access for investors to seek redress.
- Legal Expertise: DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through balanced counseling and aggressive advocacy, attracting some of the largest hedge funds and alternative asset managers as clients.
See More
Faruqi & Faruqi Encourages uniQure Investors to Reach Out
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against uniQure N.V., particularly for investors who purchased securities between September 24, 2025, and October 31, 2025, indicating concerns over the company's legal liabilities.
- Investor Rights Reminder: The firm reminds investors that April 13, 2026, is the deadline to seek the role of lead plaintiff, highlighting the opportunity for investors to participate in legal action and seek compensation.
- Direct Contact Channels: Investors can reach out directly to attorney Josh Wilson by calling 877-247-4292 or 212-983-9330 (Ext. 1310), ensuring they receive timely legal support and consultation.
- Background of Securities Class Action: This investigation is related to a federal securities class action already filed against uniQure, reflecting market concerns over potential financial misconduct by the company, which could impact its stock price and investor confidence.
See More
Reminder for uniQure Shareholder Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure N.V. (NASDAQ: QURE) shares between September 24 and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that uniQure failed to adequately disclose FDA approval status regarding its pivotal study for Huntington's disease, resulting in investor losses when the true information became public, highlighting a lack of transparency in clinical trials.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating a strong track record and extensive experience, urging investors to choose qualified legal counsel wisely.
- Investor Action Steps: Investors can visit the Rosen Law Firm website or call the toll-free number for more information; although the class has not yet been certified, investors may choose to retain counsel or remain absent, with future recovery opportunities not contingent on being a lead plaintiff.
See More
Reminder for uniQure Shareholders on Class Action Lawsuit
- Class Action Notification: Rosen Law Firm reminds investors who purchased ordinary shares of uniQure N.V. (NASDAQ:QURE) between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, allowing investors to pursue claims without financial burden.
- Lawsuit Background: The lawsuit alleges that uniQure failed to fully disclose FDA approval status and delays in its Biologics License Application for its Huntington's disease drug candidate, resulting in investor losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource capabilities in handling such cases.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action Lawsuit
- FDA Criticism: An FDA official labeled uniQure's lead gene therapy candidate AMT-130 as a “failed therapy” during a media call, accusing the company of conducting a “distorted or manipulated comparison” in clinical studies, which could undermine investor confidence in the company's future prospects.
- Surgical Requirement Controversy: The FDA official dismissed uniQure's ethical concerns regarding sham surgeries, clarifying that the agency did not request “drilling holes” but rather “one to three nicks in the scalp” under minimal anesthesia, potentially straining the company's relationship with the FDA.
- Legal Action Developments: The securities class action against uniQure alleges that the company failed to disclose that the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130, with this omission likely leading to significant investor losses as the stock price plummeted.
- Critical Deadline: Investors must apply to be Lead Plaintiff by April 13, 2026, and failure to act promptly may result in losing the opportunity to represent their interests in the lawsuit, further intensifying scrutiny on the company's governance and transparency.
See More
uniQure Faces Securities Class Action Update Amid FDA Criticism
- Deadline Reminder: Hagens Berman law firm reminds investors that the Lead Plaintiff deadline for the securities class action against uniQure N.V. is April 13, 2026, and investors must apply by this date to represent others in the lawsuit.
- FDA Criticism Raises Concerns: On March 5 and 6, 2026, FDA officials labeled uniQure's gene therapy candidate AMT-130 as a 'failed therapy,' accusing the company of making 'distorted or manipulated comparisons' in its interactions with the FDA, which could negatively impact the company's reputation and stock price.
- Overview of Allegations: The securities class action, Scocco v. uniQure N.V., alleges that throughout the Class Period from September 24 to October 31, 2025, uniQure failed to disclose critical interactions with the FDA, potentially leading investors to make decisions without fully understanding the risks, thereby affecting the company's market performance.
- Whistleblower Incentives: Hagens Berman encourages insiders to utilize the SEC Whistleblower program, where providing original information can yield rewards of up to 30% of any successful recovery, which may attract more insiders to participate in the investigation, potentially impacting uniQure's future.
See More
uniQure Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: DJS Law Group alerts investors of a class action lawsuit against uniQure N.V. (NASDAQ:QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act, covering the trading period from September 24, 2025, to October 31, 2025, with a deadline for participation by April 13, 2026.
- False Statements Allegation: The complaint alleges that uniQure made false and misleading statements regarding its pivotal study design, failing to achieve full FDA approval and underestimating potential delays in its BLA application, which materially misled investors during the class period.
- Investor Losses: Affected shareholders are encouraged to contact DJS Law Group to participate in the recovery process, noting that appointment as lead plaintiff is not a prerequisite for participation, thus providing broader access for investors to seek redress.
- Legal Expertise: DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through balanced counseling and aggressive advocacy, attracting some of the largest hedge funds and alternative asset managers as clients.
See More
Faruqi & Faruqi Encourages uniQure Investors to Reach Out
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against uniQure N.V., particularly for investors who purchased securities between September 24, 2025, and October 31, 2025, indicating concerns over the company's legal liabilities.
- Investor Rights Reminder: The firm reminds investors that April 13, 2026, is the deadline to seek the role of lead plaintiff, highlighting the opportunity for investors to participate in legal action and seek compensation.
- Direct Contact Channels: Investors can reach out directly to attorney Josh Wilson by calling 877-247-4292 or 212-983-9330 (Ext. 1310), ensuring they receive timely legal support and consultation.
- Background of Securities Class Action: This investigation is related to a federal securities class action already filed against uniQure, reflecting market concerns over potential financial misconduct by the company, which could impact its stock price and investor confidence.
See More
Reminder for uniQure Shareholder Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure N.V. (NASDAQ: QURE) shares between September 24 and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that uniQure failed to adequately disclose FDA approval status regarding its pivotal study for Huntington's disease, resulting in investor losses when the true information became public, highlighting a lack of transparency in clinical trials.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating a strong track record and extensive experience, urging investors to choose qualified legal counsel wisely.
- Investor Action Steps: Investors can visit the Rosen Law Firm website or call the toll-free number for more information; although the class has not yet been certified, investors may choose to retain counsel or remain absent, with future recovery opportunities not contingent on being a lead plaintiff.
See More
Reminder for uniQure Shareholders on Class Action Lawsuit
- Class Action Notification: Rosen Law Firm reminds investors who purchased ordinary shares of uniQure N.V. (NASDAQ:QURE) between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, allowing investors to pursue claims without financial burden.
- Lawsuit Background: The lawsuit alleges that uniQure failed to fully disclose FDA approval status and delays in its Biologics License Application for its Huntington's disease drug candidate, resulting in investor losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource capabilities in handling such cases.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action Lawsuit
- FDA Criticism: An FDA official labeled uniQure's lead gene therapy candidate AMT-130 as a “failed therapy” during a media call, accusing the company of conducting a “distorted or manipulated comparison” in clinical studies, which could undermine investor confidence in the company's future prospects.
- Surgical Requirement Controversy: The FDA official dismissed uniQure's ethical concerns regarding sham surgeries, clarifying that the agency did not request “drilling holes” but rather “one to three nicks in the scalp” under minimal anesthesia, potentially straining the company's relationship with the FDA.
- Legal Action Developments: The securities class action against uniQure alleges that the company failed to disclose that the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130, with this omission likely leading to significant investor losses as the stock price plummeted.
- Critical Deadline: Investors must apply to be Lead Plaintiff by April 13, 2026, and failure to act promptly may result in losing the opportunity to represent their interests in the lawsuit, further intensifying scrutiny on the company's governance and transparency.
See More
uniQure Faces Securities Class Action Update Amid FDA Criticism
- Deadline Reminder: Hagens Berman law firm reminds investors that the Lead Plaintiff deadline for the securities class action against uniQure N.V. is April 13, 2026, and investors must apply by this date to represent others in the lawsuit.
- FDA Criticism Raises Concerns: On March 5 and 6, 2026, FDA officials labeled uniQure's gene therapy candidate AMT-130 as a 'failed therapy,' accusing the company of making 'distorted or manipulated comparisons' in its interactions with the FDA, which could negatively impact the company's reputation and stock price.
- Overview of Allegations: The securities class action, Scocco v. uniQure N.V., alleges that throughout the Class Period from September 24 to October 31, 2025, uniQure failed to disclose critical interactions with the FDA, potentially leading investors to make decisions without fully understanding the risks, thereby affecting the company's market performance.
- Whistleblower Incentives: Hagens Berman encourages insiders to utilize the SEC Whistleblower program, where providing original information can yield rewards of up to 30% of any successful recovery, which may attract more insiders to participate in the investigation, potentially impacting uniQure's future.
See More
